MARKET

TLSA

TLSA

Tiziana Life Sciences Ltd Com
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7075
-0.0224
-3.07%
Closed 17:32 08/10 EDT
OPEN
0.7153
PREV CLOSE
0.7299
HIGH
0.7400
LOW
0.6700
VOLUME
46.87K
TURNOVER
--
52 WEEK HIGH
4.200
52 WEEK LOW
0.5301
MARKET CAP
72.36M
P/E (TTM)
-3.0055
1D
5D
1M
3M
1Y
5Y
Is Tiziana Life Sciences (NASDAQ:TLSA) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Simply Wall St. · 08/01 13:05
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
Study conducted in animal models of Alzheimer’s disease finds restored microglia homeostasis and improvement in cognitionNEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology comp...
GlobeNewswire · 08/01 12:00
Tiziana appoints former Endo exec as chief medical officer
Tiziana Life Sciences (NASDAQ:TLSA) <a href="https://se...
Seekingalpha · 07/18 11:05
Tiziana Life Sciences Named Matthew W. Davis, MD, RPh as Chief Medical Officer and Acting Chief Scientific Officer
Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has appointed Matthew Davis, MD, RPh as its Chief Medical Offic...
Benzinga · 07/18 10:12
BRIEF-Tiziana Life Sciences Reports Resignation Of CEO
BRIEF-Tiziana Life Sciences Reports Resignation Of CEO
Reuters · 07/15 20:18
Tiziana Life Sciences CEO Kunwar Shailubhai Resigns; Executive Chairman Gabriele Cerrone Named Interim CEO
MT Newswires · 07/15 16:38
Nasdaq sends non-compliance notice to Tiziana Life Sciences
Nasdaq Stock Market LLC sent a non-compliance notice to the biotechnology company Tiziana Life Sciences (NASDAQ:TLSA) over minimum bid price requirement for continued listing. The notice, received Jun. 14, stated that
Seekingalpha · 06/17 21:31
BRIEF-Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
reuters.com · 06/17 20:32
More
No Data
Learn about the latest financial forecast of TLSA. Analyze the recent business situations of Tiziana Life Sciences Ltd Com through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average TLSA stock price target is 4.833 with a high estimate of 7.50 and a low estimate of 3.000.
High7.50
Average4.833
Low3.000
Current 0.7075
EPS
Actual
Estimate
-0.95-0.71-0.48-0.24
2019/06
2019/12
2020/06
2020/12
2021/06
Institutional Holdings
Institutions: 25
Institutional Holdings: 5.73M
% Owned: 5.60%
Shares Outstanding: 102.27M
TypeInstitutionsShares
Increased
4
69.89K
New
6
151.32K
Decreased
4
86.55K
Sold Out
7
224.73K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
Chairman/Director
Gabriele Cerrone
Chief Executive Officer/Chief Scientific Officer/Director
Kunwar Shailubhai
Other
Neil Graham
Non-Executive Independent Director
John Brancaccio
Non-Executive Independent Director
Willy Simon
No Data
No Data
About TLSA
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company. The Company specializes in developing transformative therapies for neurodegenerative diseases and gastrointestinal diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Crohn's Disease and KRAS+ NSCLC. The Company’s lead immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Crohn's disease, Pro-MS and autoimmune diseases, and its Milciclib (TZLS-201), is an orally bioavailable, small molecule, spectrum inhibitor of cyclin-dependent kinases (CDKs) (a family of highly conserved enzymes that regulate the cell cycle and cell division) and Src family kinases, which involved in regulating cell growth and potential transformation of normal cells to cancer cells. The Company is also focused on Anti Interlukin-6 Receptor mAB (TZLS-501), which is a fully human mAb that binds to both membrane-bound and soluble forms of IL-6R.

Webull offers kinds of Tiziana Life Sciences Ltd - ADR stock information, including NASDAQ:TLSA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TLSA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TLSA stock methods without spending real money on the virtual paper trading platform.